Bristol-Myers Squibb Company — Earnings Quality Grade F
BMY · Healthcare
Major red flags
Screening Summary
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 73 days, change +5 days YoY
AR growth 6.4% vs revenue growth -0.2%
Revenue -0.2%, CFFO -6.8%. Cash follows revenue
Expense Quality
Inventory 5.2% vs COGS -0.2%. Normal
CapEx growth 5.0% vs revenue -0.2%. Normal
SG&A/Gross Profit = 21.2%, excellent (<30%)
Gross margin 71.1%, change +0.0pp. Stable
Cash Flow Quality
CFFO/NI = 2.01. Profits backed by cash
FCF $12.8B, FCF/NI = 1.82
Accruals ratio = -7.9%. Low accruals
Cash $10.7B covers only 23% of debt $47.1B
Balance Sheet Health
Goodwill+Intangibles $41.1B = 223% of equity. Over 50%
Debt/EBITDA = 3.1x. Healthy
Other assets 3.7% vs revenue -0.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change -9% YoY. Normal
Manipulation Score
M-Score = -2.68 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-09